Primary and secondary prevention of heart failure with statins

References

• Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366(9493), 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation97(3), 282–289 (1998).
   PubMed Web of Science ®Google Scholar
• Fox KF, Cowie MR, Wood DA et al. Coronary artery disease as the cause of incident heart failure in the population. Eur. Heart J.22(3), 228–236 (2002).
   Google Scholar
• Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol22(4 Suppl. A), 6A–13A (1993).
   PubMedGoogle Scholar
• Cowie MR, Mosterd A, Wood DA et al. The epidemiology of chronic heart failure. Eur. Heart J.18(2), 208–225 (1997).
   PubMed Web of Science ®Google Scholar
• Eriksson H, Svardsudd K, Larsson B et al. Risk factors for heart failure in the general population: the study of men born in 1913. Eur. Heart J.10(7), 647–656 (1989).
   PubMed Web of Science ®Google Scholar
• Sharpe N, Doughty R. Epidemiology of chronic heart failure and ventricular dysfunction. Lancet352(Suppl. 1), S13–S17 (1998).
   PubMedGoogle Scholar
• Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am. Heart J.121(6 Pt 1), 1852–1853 (1991).
   PubMed Web of Science ®Google Scholar
• Uretsky BF, Thygesen K, Armstrong PW et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation102(6), 611–616 (2000).
   PubMed Web of Science ®Google Scholar
• Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br. Heart J.72(Suppl. 2), S3–S9 (1994).
   PubMedGoogle Scholar
• Polanczyk CA, Rohde LE, Dec GW, DiSalvo T. Ten-year trends in hospital care for congestive heart failure: improved outcomes and increased use of resources. Arch. Int. Med.160(3), 325–332 (2000).
   PubMedGoogle Scholar
• Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur. Heart J.4(3), 361–371 (2002).
   Google Scholar
• Parmley WW. Cost-effective management of heart failure. Clin. Cardiol.19(3), 240–242 (1996).
   PubMedGoogle Scholar
• Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet362(9378), 147–158 (2003).
   PubMed Web of Science ®Google Scholar
• Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increased mortality in advanced heart failure. J. Card. Fail.8(4), 216–224 (2002).
   PubMed Web of Science ®Google Scholar
• Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J. Am. Coll. Cardiol42(11), 1933–1940 (2003).
   PubMed Web of Science ®Google Scholar
• Anker SD, Rauchhaus M. Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. Curr. Opin. Cardiol.14(3), 211–216 (1999).
   PubMedGoogle Scholar
• Liu Y, Coresh J, Eustace JA et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA291(4), 451–459 (2004).
   PubMed Web of Science ®Google Scholar
• Anonymous. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344(8934), 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Sheperd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.333(20), 1301–1307 (1995).
   PubMedGoogle Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med.335(14), 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med.339(19), 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA279(20), 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326), 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet360(9346), 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA285(13), 1711–1718 (2001).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA288(23), 2998–3007 (2002).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet361(9364), 1149–1158 (2005).
   Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): a multicentre randomized placebo-controlled trial. Lancet364(9435), 685–696 (2004).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA291(9), 1071–1080 (2004).
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA292(11), 1307–1316 (2004).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352(14), 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA294(19), 2437–2445 (2005).
   PubMed Web of Science ®Google Scholar
• Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet356(9233), 930–933 (2000).
   PubMed Web of Science ®Google Scholar
• Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J. Am. Coll. Cardiol39, 1567–1573 (2002).
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet353(9157), 983–984 (1999).
   PubMed Web of Science ®Google Scholar
• Sola S, Mir MQS, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am. Coll. Cardiol47(2), 332–337 (2006).
   PubMed Web of Science ®Google Scholar
• Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation108(17), 839–843 (2003).
   PubMed Web of Science ®Google Scholar
• Laufs U, Wassmann S, Schackmann S, Heeschen C, Bohm M, Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z. Kardiol.93(2), 103–108 (2004).
   PubMedGoogle Scholar
• Wojnicz R, Wilczek K, Nowalany-Kozielska E et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am. J. Cardiol.97(6), 899–904 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA279(20), 1643–1650 (1998).
   PubMed Web of Science ®Google Scholar
• O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG–coenzyme a reductase inhibitor, improves endothelial function within 1 month. Circulation95(5), 1126–1131 (1997).
   PubMed Web of Science ®Google Scholar
• Strey CH, Young JM, Molyneux SL et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis179(1), 201–206 (2005).
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Antoniades C, Bosinakou E et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart91(1), 27–31 (2005).
   PubMed Web of Science ®Google Scholar
• Hayashidani S, Tsutsui H, Shiomi T et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation105(7), 868–873 (2002).
   PubMed Web of Science ®Google Scholar
• de Lorgeril M, Salen P, Bontemps L, Belichard P, Geyssant A, Itti R. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J. Cardiovasc. Pharm.33(3), 473–478 (1999).
   PubMedGoogle Scholar
• Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation107(19), 2493–2498 (2003).
   PubMed Web of Science ®Google Scholar
• Young-Xu Y, Jabbour S, Goldberg R et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am. J. Cardiol.92(12), 1379–1383 (2003).
   PubMed Web of Science ®Google Scholar
• Benedict CR, Shelton B, Johnstone DE et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation94(4), 690–697 (1996).
   PubMed Web of Science ®Google Scholar
• Mosterd A, Cost B, Hoes AW et al. The prognosis of heart failure in the general population: The Rotterdam Study. Eur. Heart J.22(15), 1318–1327 (2001).
   PubMed Web of Science ®Google Scholar
• Bleske BE, Nicklas JM, Bard RL et al. Neutral effects on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am. Coll. Cardiol47(2), 338–341 (2006).
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Pederson TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure with coronary heart disease. J. Card. Fail.3(4), 249–254 (1997).
   PubMedGoogle Scholar
• Lewis SJ, Moye LA, Sacks FM et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) trial. Ann. Intern. Med.129(9), 681–689 (1998).
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥ 125 mg/dl treated with statins versus no lipid-lowering drug. Am. J. Cardiol.90(2), 147–149 (2002).
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA, Cannon CP et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 25 study. J. Am. Coll. Cardiol47(11), 2326–2331 (2006).
   PubMedGoogle Scholar
• Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP, and the AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J. Am. Coll. Cardiol42(1), 81–87 (2003).
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am. J. Cardiol.93(9), 1124–1129 (2004).
   PubMed Web of Science ®Google Scholar
• Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J. Am. Coll. Cardiol43(4), 642–648 (2004).
   PubMed Web of Science ®Google Scholar
• Ezekowitz J, McAlister FA, Humphries KH et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J. Am. Coll. Cardiol44(8), 1587–1592 (2004).
   PubMed Web of Science ®Google Scholar
• Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation112(3), 357–363 (2005).
   PubMed Web of Science ®Google Scholar
• Sola S, Mir MQS, Rajagopalan S, Helmy T, Tandon N, Khan BV. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J. Card. Fail.11(8), 607–612 (2005).
   PubMedGoogle Scholar
• Anker SD, Clark AL, Winkler R et al. Statin use and survival in patients with chronic heart failure – results from two observational studies with 5200 patients. Int. J. Cardiol.112(2), 234–242 (2006).
   PubMed Web of Science ®Google Scholar
• Ray JG, Gong Y, Sykora K, Tu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch. Intern. Med.165(1), 62–67 (2005).
   PubMedGoogle Scholar
• Foody JM, Shah R, Galusha D et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation113(8), 1086–1092 (2005).
   Google Scholar
• Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med.334(21), 1349–1355 (1996).
   PubMed Web of Science ®Google Scholar
• Anonymous. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet353(9146), 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med.341(10), 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur. J. Heart. Fail.7(6), 1059–1069 (2005).
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Tognoni G, Franzosi MG et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur. J. Heart. Fail.6(5), 635–641 (2004).
   PubMed Web of Science ®Google Scholar